PHYSIOTHERAPY FOR MULTIPLE SCLEROSIS PATIENTSHumansMultiple SclerosisMovement DisordersExercise TherapyOrthopedic EquipmentPhysical Therapy ModalitiesMuscle SpasticityPHYSIOTHERAPY FOR MULTIPLE SCLEROSIS PATIENTS. By - L.H. De Souzadoi:10.1016/S0140-6736(83)92391-7De Souza...
作者: De Souza,L.H. 摘要: PHYSIOTHERAPY FOR MULTIPLE SCLEROSIS PATIENTS. By - L.H. De Souza 关键词: Humans Multiple Sclerosis Movement Disorders Exercise Therapy Orthopedic Equipment Physical Therapy Modalities Muscle Spasticity DOI: 10.1016/S0140-6736(83)92391-7 被引量: 2 年份: 1983 收...
BACKGROUND: Multiple sclerosis (MS) patients are referred to occupational therapy with complaints about fatigue, limb weakness, alteration of upper extremity fine motor coordination, loss of sensation and spasticity that causes limitations in performance of activities of daily living and social participatio...
The purpose of the next webinar is to discuss the most important questions about treatment for patients with Multiple Sclerosis and other Autoimmune Diseases. HSCT for MS: New Updated Results & Approaches 2024, Future Directions 2025+ 1. The results of the most effective and safest «R-Flu/Cp...
Our compassionate approach to the well-being of multiple sclerosis patients and their loved ones, coupled with a commitment to rigorous multiple sclerosis research makes us your first choice for comprehensive MS care. Neurology Consultation Our specialist in the treatment of the brain, nerves, and mu...
Improving psychological resilience in patients with multiple sclerosis may be a promising approach to enhancing their quality of life. Previous studies have suggested that resilience may be a stable personality trait. However, it is now understood that resilience is dynamic and focused on individual ...
Treating multiple sclerosis costs a great deal for patients and communities. Individually, the nearly 1 million people with MS pay an average annual cost of more than $88,000 for the various treatment options, devices, daily living needs, and insurance needed for their condition. Overall, indirec...
Pathogenic autoantibodies in multiple sclerosis—from a simple idea to a complex concept. Nat. Rev. Neurol. 18, 681–688 (2022). Article PubMed Google Scholar Kuerten, S. et al. Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients...
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these
Leading multiple sclerosis (MS) therapies have patient support programs (PSPs) aimed at improving patients' lives. There is limited knowledge about what drives patient satisfaction with PSPs and little evidence about its impact on patient-reported health status or health-related quality of life. The...